WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Thursday, February 25, 2016

Michael J. Fox Foundation Partners with Charles River Laboratories on Parkinson’s Research

Feb. 25, 2016

The Michael J. Fox Foundation, an organization devoted to supporting the diagnosis and treatment of Parkinson’s disease, has expanded its collaboration with contract research organization, Charles River Laboratories.  The two are working together to investigate mutations in the LRRK2 gene, which are the greatest known genetic causes of Parkinson’s disease (PD). The team seeks to develop a mouse model of PD to understand the effects of LRRK2 inhibitors as a novel therapeutic strategy in preventing the progression of the disease. Experts from Charles River Laboratories (CRL) spoke to Bioscience Technology and answered a few questions about the partnership and research goals.
David Fischer, Ph.D., is Executive Director of Biology and Drug Metabolism and Pharmacokinetics Discovery and Robert Hodgson, Ph.D., is Director of Science, Research and Discovery, Discovery Site Operations, at Charles River Laboratories.
Why did The Michael J. Fox Foundation (MJFF) decide to partner with a contract research organization (CRO)? Are these kinds of partnerships becoming more common, and if so why?
We have the ability to provide MJFF with a large suite of assays that could be used to fully characterize a novel animal model and to help identify a therapeutic window for LRRK2 inhibitors as a class. As a CRO, we are able to evaluate compounds from multiple pharmaceutical companies working on this target without any bias, providing a fully objective readout of their molecules. And on the in vitro side, our chemistry expertise and strong project management have proven useful on a separate MJFF-led project to develop a positron emission tomography (PET) radiotracer to visualize the distribution of alpha-synuclein aggregates found in pathological conditions characterized by Lewy bodies, such as Parkinson's disease. Relationships that involve multiple companies to form a pre-competitive consortium have become more common, and MJFF is perhaps the best example in our industry of an organization that breaks down barriers that have historically impeded collaboration.   
How will this new work being carried out with the MJFF build on previous research?
CRL previously worked with other clients to develop selective LRRK2 inhibitors that cross the blood-brain-barrier (J Med Chem 55 (22): 9416-9433). We are also able to work with a high number of PD-relevant endpoints in rodents, making it an ideal CRO with whom to partner in order to achieve assessments of novel animal models, compound effectiveness and validation of novel biomarker strategies. Finally, we have the ability to provide data-rich analyses of any of these approaches by tying together these multiple readouts in the same animal.
How significant a role do small-molecule LRRK2 inhibitors play in Parkinson’s drug development? And what makes them such promising drug targets? 
For neurodegenerative diseases, it is challenging to find novel targets that have strong human validation. LRRK2 is an exception. Mutations in LRRK2 are the most common genetic cause of Parkinson’s disease. Although the majority of Parkinson’s disease is not caused by single gene mutations, targeting the same pathway in patients with sporadic Parkinson’s disease as well as in LRRK2 carriers is thought to be a potential disease-modifying approach. 
What are the biggest challenges researchers face working with LRRK2 inhibitors and the enzyme they target?
A major challenge to developing LRRK2 inhibitors is making sure they cross the blood-brain-barrier as PD is a disorder of the central nervous system. In addition, pharmacodynamic biomarkers are needed to guide dose-efficacy relationship predictions. Genetic animal models involving LRRK2 over-expression have not historically generated a robust phenotype, which makes pharmacodynamic and pre-clinical efficacy studies difficult. This is why CRL works closely with The Michael J. Fox Foundation to improve on existing animal models that can drive forward research to discover new treatments or cures for PD.
What is it about Charles River’s in vitro biology expertise that makes you well-suited for developing a screening assay for protein aggregation?
CRL’s leadership in high-throughput screening, combined with CRL’s expertise in human primary cells and stem cells allows us to develop novel screening assays for alpha-synuclein in vitro biology.
Can you describe the scope and progress of other research projects with the MJFF, particularly the development of an a-synuclein imaging agent?
Since 2011, we have been part of an MJFF-led consortium to discover and develop a novel PET imaging agent for Lewy bodies, the neuropathological hallmark of Parkinson’s disease.  CRL works together with a number of academic and industry partners that contribute unique reagents and brain material to help us optimize the molecules towards these highly needed imaging agents.
http://www.biosciencetechnology.com/news/2016/02/michael-j-fox-foundation-partners-charles-river-laboratories-parkinsons-research

No comments:

Post a Comment